(-0.12%) 5 141.00 points
(-0.08%) 38 528 points
(-0.06%) 17 894 points
(-0.34%) $82.35
(1.33%) $2.06
(-1.03%) $2 333.40
(-2.21%) $27.05
(-0.55%) $956.20
(0.29%) $0.935
(0.59%) $11.05
(0.27%) $0.798
(-0.28%) $93.04
Live Chart Being Loaded With Signals
Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality...
Stats | |
---|---|
本日の出来高 | 29 100.00 |
平均出来高 | 92 366.00 |
時価総額 | 161.14B |
EPS | ¥0 ( 2024-01-30 ) |
次の収益日 | ( ¥110.76 ) 2024-05-06 |
Last Dividend | ¥40.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 13.59 |
ATR14 | ¥3.41 (0.09%) |
ボリューム 相関
Kissei Pharmaceutical 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Kissei Pharmaceutical 相関 - 通貨/商品
Kissei Pharmaceutical 財務諸表
Annual | 2022 |
収益: | ¥67.49B |
総利益: | ¥32.38B (47.97 %) |
EPS: | ¥228.30 |
FY | 2022 |
収益: | ¥67.49B |
総利益: | ¥32.38B (47.97 %) |
EPS: | ¥228.30 |
FY | 2022 |
収益: | ¥65.38B |
総利益: | ¥31.24B (47.78 %) |
EPS: | ¥280.20 |
FY | 2021 |
収益: | ¥69.04B |
総利益: | ¥32.72B (47.39 %) |
EPS: | ¥113.25 |
Financial Reports:
No articles found.
Kissei Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥40.00 (N/A) |
¥0 (N/A) |
¥40.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥7.00 | 2001-03-27 |
Last Dividend | ¥40.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 46 | -- |
Total Paid Out | ¥794.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.68 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.36 | |
Div. Directional Score | 7.40 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8383.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7782.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
6951.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6306.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
5074.T | Ex Dividend Junior | 2024-06-27 | Annually | 0 | 0.00% | |
4229.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3451.T | Ex Dividend Junior | 2023-10-30 | Semi-Annually | 0 | 0.00% | |
2590.T | Ex Dividend Knight | 2024-01-18 | Semi-Annually | 0 | 0.00% | |
9502.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8104.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.165 | 1.500 | 6.69 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0534 | 1.200 | 8.22 | 9.86 | [0 - 0.3] |
returnOnEquityTTM | 0.0620 | 1.500 | -0.422 | -0.634 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.93 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.22 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.155 | 1.500 | 4.69 | 7.04 | [0.2 - 2] |
debtRatioTTM | 0.00608 | -1.500 | 9.90 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 141.28 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 186.97 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 186.97 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00707 | -1.500 | 9.97 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.482 | 1.000 | 5.29 | 5.29 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0345 | 1.000 | -1.310 | -1.310 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 6.04 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.323 | 0.800 | -1.182 | -0.946 | [0.5 - 2] |
Total Score | 10.43 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 13.21 | 1.000 | 8.77 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0620 | 2.50 | -0.272 | -0.634 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 186.97 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.29 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 186.97 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0896 | 1.500 | -2.74 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.114 | 1.000 | 9.65 | 0 | [0.1 - 0.5] |
Total Score | 4.36 |
Kissei Pharmaceutical
Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。